文献速递其他结缔组织病

不完美的风暴:白细胞介素-33是COVID-19的阿喀琉斯之踵吗?

Imperfect storm: is interleukin-33 the Achilles heel of COVID-19?
PubMed 文献 · Lancet Rheumatol · 2020-10-09

该文提出一种致病模型,认为警报素细胞因子IL-33是驱动COVID-19无症状、轻中度、重危和慢性纤维化各阶段的关键因素。在易感个体中,受损下呼吸道细胞释放的IL-33可能诱导失调的GATA结合因子3表达调节性T细胞,打破免疫耐受并引发SARS-CoV-2诱导的自身炎症性肺病。文章讨论了靶向IL-33等通路的治疗意义。

要点

  • IL-33释放可能诱导失调的GATA3表达调节性T细胞,打破免疫耐受。
  • IL-33-ST2轴可能扩增致病性GM-CSF表达T细胞、抑制抗病毒干扰素并促血栓。
  • IL-33可能通过诱导肌成纤维细胞和上皮间质转化驱动肺纤维化。

核心结论

  • IL-33可能是驱动COVID-19各阶段疾病的关键警报素细胞因子。

研究设计与样本

  • 原文为Lancet Rheumatol发表的假说性综述,提出COVID-19的IL-33致病模型并讨论治疗意义。

主要发现

  • 在易感个体中,IL-33释放可能诱导失调的GATA结合因子3表达调节性T细胞,打破免疫耐受。
  • IL-33分化的2型固有淋巴细胞和局部扩增的γδ T细胞可能初始维持该自身炎症性肺病。
  • 在重症COVID-19中,IL-33-ST2轴可能扩增致病性粒细胞-巨噬细胞集落刺激因子表达T细胞、抑制抗病毒干扰素反应、引发过度炎症并促进血栓形成。
  • 在重症存活者中,IL-33可能通过诱导肌成纤维细胞和上皮间质转化驱动肺纤维化。

临床怎么用

  • 原文讨论靶向IL-33(如抗ST2)、Th17样γδ T细胞、免疫细胞归巢和细胞因子平衡等治疗策略的潜在意义。

局限性

  • 原文所述IL-33驱动COVID-19各阶段的通路为假说性模型,尚需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The unique cytokine signature of COVID-19 might provide clues to disease mechanisms and possible future therapies. Here, we propose a pathogenic model in which the alarmin cytokine, interleukin (IL)-33, is a key player in driving all stages of COVID-19 disease (ie, asymptomatic, mild-moderate, severe-critical, and chronic-fibrotic). In susceptible individuals, IL-33 release by damaged lower respiratory cells might induce dysregulated GATA-binding factor 3-expressing regulatory T cells, thereby breaking immune tolerance and eliciting severe acute respiratory syndrome coronavirus 2-induced autoinflammatory lung disease. Such disease might be initially sustained by IL-33-differentiated type-2 innate lymphoid cells and locally expanded γδ T cells. In severe COVID-19 cases, the IL-33-ST2 axis might act to expand the number of pathogenic granulocyte-macrophage colony-stimulating factor-expressing T cells, dampen antiviral interferon responses, elicit hyperinflammation, and favour thromboses. In patients who survive severe COVID-19, IL-33 might drive pulmonary fibrosis by inducing myofibroblasts and epithelial-mesenchymal transition. We discuss the therapeutic implications of these hypothetical pathways, including use of therapies that target IL-33 (eg, anti-ST2), T helper 17-like γδ T cells, immune cell homing, and cytokine balance.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Zizzo G, Cohen PL. Imperfect storm: is interleukin-33 the Achilles heel of COVID-19? Lancet Rheumatol. 2020. PMID: 33073244. doi:10.1016/S2665-9913(20)30340-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。